Adocia : M1Pram cristallise les attentions à court terme
>Accord avec Sanofi pour M1Pram comme principal catalyseur de court terme - Nous avons eu l’occasion cette semaine d’accompagner Adocia en roadshow avec Olivier Soula (CEO) et Valérie Danaguezian (CFO). Ceci a été l’occasion pour le management de la biotech de revenir sur l’avancement des différents actifs de son pipeline et de faire le point sur les catalyseurs à venir. La potentielle conclusion d’un accord de partenariat global avec Sanofi pour le M1Pram sera au cœu...ADOCIA is a biotechnology company based in France. Co. specializes in the development of formulations for already-approved therapeutic proteins with a primary focus on insulins and treatments for diabetic foot ulcers. Co.'s biotherapy products are used in tissue regeneration and for treating chronic diseases. Co.'s proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins in areas such as wound Healing, diabetes, ulcers and monoclonal antibody creation. Co. also maintains activities in the formulation of monoclonal antibodies for the treatment of various chronic pathologies (oncology, inflammation, etc.).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.